Pharmaceutical innovation: Impact on expenditure and outcomes and subsequent challenges for pharmaceutical policy, with a special reference to Greece

Hippokratia

Volumn 18, Issue 2, 2014, Pages 100-106

  Karampli, Eleftheria ^a,b   Souliotis, K ^c   Polyzos, N ^b   Kyriopoulos, J ^a   Chatzaki, E ^b  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c UNIVERSITY OF PELOPONNESE   (Greece)

Author keywords

Drug costs; Greece; Innovation diffusion; Pharmaceutical economics; Pharmaceutical technology

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTACID AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; NEUROLEPTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN UPTAKE INHIBITOR;

COST CONTROL; DRUG COST; DRUG EXPOSURE; DRUG UTILIZATION; GREECE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH STATUS; HUMAN; MEDICAL TECHNOLOGY; PHARMACEUTICS; PHARMACOECONOMICS; PRESCRIPTION; REVIEW; SOCIOECONOMICS; TREATMENT OUTCOME;

EID: 84905700332     PISSN: 11084189     EISSN: 17908019     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Sorenson C, Drummond M, Kanavos P. Ensuring value for money in health care. The role of health technology assessment in the European Union, European Observatory on Health Systems and Policies, Copenhagen, 2008, 3-4.
2. Facey K. INAHTA Health Technology Assessment (HTA) Glossary [Internet]. Topfer L, Chan L(eds), INAHTA Secretariat, Cologne, DE, 2006. Available from: http://www.inahta.net/Glossary/, last accessed 2012 Nov 1.
3. Przywara B, Projecting future health care expenditure at European level: drivers, methodology and main results [Internet], European Commission, Brussels, 2010. Available from: http://ec.europa. eu/economy_finance/publications/economic_paper/2010/pdf/ ecp417_en.pdf, last accessed 2013 Feb 24.
4. Smith S, Heffler SK, Freeland MS. The Impact of Technological Change on Health Care Cost Spending: An Evaluation of the Literature [Internet], Health Care Financing Administration, Centers for Medicare and Medicaid Services, Baltimore, MD,2000. Available from: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/downloads/tech_2000_0810.pdf, last accessed 2012 Feb 21.
5. Karampli E, Chatzaki E, Polyzos N, Souliotis K, Kyriopoulos J. Determinants of health expenditure growth in developed countries. Iatriki. 2013; 102: 281-289.
6. Serra-Sastre V, McGuire A, Diffusion of health technologies: evidence from the pharmaceutical sector. Joan C-F, Courbage C, McGuire A (eds), The Economics of New Technologies: incentives, organization, and financing, Oxford University Press, New York, 2009, 53-74.
7. Charles River Associates, Innovation in the pharmaceutical sector. A study undertaken for the European Commission [Internet], European Commission, Directorate General Health & Consumers, Brussels, 2004. Available from: http://ec.europa.eu/health/ files/pharmacos/docs/doc2004/nov/eu_pharma_innovation_25-11-04_en.pdf, last accessed 2014 Jan 14.
8. Morgan S, Lopert R, Greyson D. Toward a definition of pharmaceutical innovation. Open Med. 2008; 2: e4-e7.
9. Motola D, De Ponti F, Poluzzi E, Martini N, Rossi P, Silvani MC, et al. An update on the first decade of the European centralized procedure: how many innovative drugs? Br J ClinPharmacol. 2006; 62: 610-616.
10. OECD, Pharmaceutical Pricing Policies in a Global Market, OECD Publishing, Paris, 2008, 29.
11. OECD, Health spending continues to stagnate, says OECD [Internet], Organisation for Economic Co-operation and Development, Paris, 2013. Available from: http://www.oecd.org/ els/health-systems/health-spending-continues-to-stagnate-saysoecd.htm, last accessed 2013 Jun 30.
12. Ryu AJ, Gibson TB, McKellar MR, Chernew ME. The slowdown in health care spending in 2009-11 reflected factors other than the weak economy and thus may persist. Health Aff (Millwood). 2013; 32: 835-840.
13. Kaiser Family Foundation. Assessing the Effects of the Economy on the Recent Slowdown in Health Spending [Internet], Kaiser Family Foundation, Menlo Park, CA, 2013. Available from: http://kff.org/health-costs/issue-brief/assessing-the-effects-ofthe-economy-on-the-recent-slowdown-in-health-spending-2/, last accessed 2013 Aug 31.
14. de la Maisonneuve C, Oliveira Martins J, Public spending on health and long-term care: a new set of projections [Internet], OECD Publishing, Paris, 2013. Available from: http://www. oecd.org/eco/growth/Health%20FINAL.pdf, last accessed 2013 Aug 31.
15. Gerdtham UG, Johannesson M, Gunnarsson B, Marcusson M, Henriksson F. The effect of changes in treatment patterns on drug expenditure. Pharmacoeconomics. 1998; 13: 127-134.
16. Addis A, Magrini N. New approaches to analysing prescription data and to transfer pharmacoepidemiological and evidencebased reports to prescribers. Pharmacoepidemiol Drug Saf. 2002; 11: 721-726.
17. Gerdtham UG, Lundin D. Why did drug spending increase during the 1990s? A decomposition based on Swedish data. Pharmacoeconomics. 2004; 22: 29-42.
18. Hsieh CR, Sloan FA. Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective? Value Health. 2008; 11: 334-344.
19. Wu J, Yue N, Xu W. Increasing Anti-Infective Drug Expenditure in Tianjin, China: A Decomposition Analysis. Value Health Regional Issues. 2013; 2:37-42.
20. Lambrelli D, O'Donnell O. The impotence of price controls: failed attempts to constrain pharmaceutical expenditures in Greece. Health Policy. 2011; 101: 162-171.
21. Mousnad MA, Shafie AA, Mohamed Ibrahim MI. Determination of the main factors contributing to increases in medicine expenditures for the National Health Insurance Fund in Sudan. J Pharm HealthServ Res. 2013; 4: 159-164.
22. Mossialos E, Mrazek MF, Walley T (eds). Regulating Pharmaceuticals In Europe: Striving For Efficiency, Equity, And Quality, Open University Press, Berkshire, 2004, 12.
23. Morgan SG. Booming prescription drug expenditure: apopulation-based analysis of age dynamics. Med Care. 2005; 43: 996-1008.
24. Reinhardt UE. Does the aging of the population really drive the demand for health care? Health Aff (Millwood). 2003; 22: 27-39.
25. Busse R, van Ginneken E, Normand C, Re-examining the cost pressures on health systems, Figueras J, McKee M (eds), Health Systems, Health, Wealth and Societal Well-being: Assessing the case for investing in health systems, Open University Press, Berkshire, 2012, 37-60.
26. Morgan SG, The determinants of prescription drug expenditure. and what to do about them [Internet], University of British Columbia, Centre for Health Services and Policy Research, Vancouver, BC, 2008. Available from: http://amcp.org/WorkArea/ DownloadAsset.aspx?id=13234, last accessed 2013 Mar 3.
27. Teixeira IJ, Escoval A, Schiappa M. Lipid-lowering drugs: use and expenditure in Portugal (1995-2004). Rev Port Cardiol. 2007; 26: 475-493.
28. Jackevicius CA, Cox JL, Carreon D, Tu JV, Rinfret S, So D, et al. Canadian Cardiovascular Outcomes Research Team. Longterm trends in use of and expenditures for cardiovascular medications in Canada. CMAJ. 2009; 181: E19-E28.
29. Dubois RW, Chawla AJ, Neslusan CA, Smith MW, Wade S. Explaining drug spending trends: does perception match reality? Health Aff (Millwood). 2000; 19: 231-239.
30. Danzon PM, Pauly MV. Health Insurance and the Growth in Pharmaceutical Expenditures. J Law Econ. 2002; 45: 587-613.
31. Zhang Y, Donohue JM, Lave JR, O'Donnell G, Newhouse JP. The effect of Medicare Part D on drug and medical spending. N Engl J Med. 2009; 361: 52-61.
32. Cutler DM, McClellan M. Is technological change in medicine worth it? Health Aff (Millwood). 2001; 20: 11-29.
33. Productivity Commission (AU), Impacts of Advances in Medical Technology in Australia [Internet], Commonwealth of Australia, Melbourne, 2005. Available from: http://www.pc.gov. au/__data/assets/pdf_file/0003/17193/medicaltechnology.pdf, last accessed 2013 Feb 10.
34. Santerre RE. National and International Tests of the New Drug Cost Offset Theory. South Econ J. 2011; 77: 1033-1043.
35. Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff (Millwood). 2001; 20: 241-251.
36. Lichtenberg FR. Benefits and costs of new drugs: an update, National Bureau of Economic Research, Cambridge, MA, 2002. Available from: http://www.nber.org/papers/w8996, last accessed 2013 Feb 10.
37. Zhang Y, Soumerai SB. Do newer prescription drugs pay for themselves? A reassessment of the evidence. Health Aff (Millwood). 2007; 26: 880-886.
38. Civan A, Köksal B. The effect of newer drugs on health spending: do they really increase the costs? Health Econ. 2010; 19:581-595.
39. Karaca Z, Wiggins SN. The Impacts of Break-Through Drug Classes on Total Health Expenditures: Empirical Evidence from the 1996-2001 Medical Expenditure Panel Surveys, Social Science Research Network, Rochester, NY, 2006. Available from http://ssrn.com/abstract=947603, last accessed 2013 Feb 10.
40. Bozzette SA, Joyce G, McCaffrey DF, Leibowitz AA, Morton SC, Berry SH, et al. HIV Cost and Services Utilization Study Consortium. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001; 344: 817-823.
41. Liu YM, Hsieh CR. New drugs and the growth of health expenditure: evidence from diabetic patients in Taiwan. Health Econ. 2012; 21: 496-513.
42. Karaca-Mandic P, McCullough JS, Siddiqui MA, Van Houten H, Shah ND. Impact of new drugs and biologics on colorectal cancer treatment and costs. J OncolPract. 2011; 7: e30s-e37s.
43. Lichtenberg FR. Sources of U.S. longevity increase, 1960-1997, National Bureau of Economic Research, Cambridge, MA, 2002. Available from: http://www.nber.org/papers/w8755, last accessed 2013 Feb 10.
44. Lichtenberg FR, Duflos G. Pharmaceutical innovation and the longevity of Australians: a first look, National Bureau of Economic Research, Cambridge, MA, 2008. Available from: http:// www.nber.org/papers/w14009, last accessed 2013 Feb 10.
45. Lichtenberg FR, Virabhak S. Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as 'Equipment for Your Health'. Manage Decis Econ. 2007; 28: 371-392.
46. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338: 853-860.
47. Lichtenberg FR. The effect of new drug approvals on HIV mortality in the US, 1987-1998. Econ Hum Biol. 2003; 1: 259-266.
48. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008; 44: 1345-1389.
49. Mestre-Ferrandiz J, Garau M, O'Neill P, Sussex J. Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society [Internet], Office of Health Economics, London, 2010. Available from:http://www.europabio.org/sites/ default/files/report/assessment_of_the_impact_of_orphan_medicinal_products.pdf, last accessed 2013 Oct 5.
50. Lichtenberg FR. The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007. Eur J Health Econ. 2013; 14:41-56.
51. OECD. Value for money in health spending. OECD Publishing, Paris, 2010, 167-173.
52. Karampli E, Athanasakis K, Kyriopoulos J. Pharmacoeconomics and decision-making in health care: current situation and future trends. Iatriki. 2010; 98: 354-362.
53. Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M. Differences in costs of and access to pharmaceutical products in the EU [Internet], European Parliament, Brussels,2011. Available from: http://www.europarl.europa.eu/document/activities/cont/ 201201/20120130ATT36575/20120130ATT36575EN.pdf, last accessed 2013 Oct 28.
54. Athanasakis K, Konstantinou E, Thireos E, Kyriopoulos J. The relative value of medical innovations on population health status: Physicians' views in Greece. Archives of Hellenic Medicine. 2010; 27: 963-969.
55. Vandoros S, Stargardt T. Reforms in the Greek pharmaceutical market during the financial crisis. Health Policy. 2013; 109: 1-6.
56. Contiades X, Golna C, Souliotis K. Pharmaceutical regulation in Greece at the crossroad of change: economic, political and constitutional considerations for a new regulatory paradigm. Health Policy. 2007; 82: 116-129.
57. Lichtenberg FR. Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000-2009. Health Policy Technol. 2014; 3: 36-58.
58. Souliotis K. A (repeated) proposal for pharmaceutical policy reform in Greece. Archives of Hellenic Medicine. 2013; 30: 520-521.
59. Murtagh J. Foerster V, Managing Technology Diffusion, Canadian Agency for Drugs and Technologies in Health, Ontario, 2009. Available from: http://www.cadth.ca/media/policy_forum_section/Managing_Technology_Diffusion_e.pdf, last accessed 2013 Oct 28.